Hypocomplementemia in primary Sjogren’s syndrome: association with serological, clinical features, and outcome

Wei Lin1 · Zhifei Xin2 · Jialan Wang3 · Xiuying Ren1 · Yixuan Liu1 · Liu Yang4 · Shaoying Guo4 · Yupeng Yang5 · Yang Li6 · Jingjing Cao1 · Xiaoran Ning1 · Meilu Liu1 · Yashuang Su1 · Lijun Sun1 · Fengxiao Zhang1 · Wen Zhang7

Received: 9 November 2021 / Revised: 7 February 2022 / Accepted: 13 March 2022 / Published online: 29 March 2022
© The Author(s) 2022

Abstract
Objective The aim of the present study was to assess the clinical characteristic of hypocomplementemia (HC) in primary Sjogren’s syndrome (pSS), and to address possible risk factors and the prognosis associated with HC in pSS patients.

Methods pSS patients with HC in Hebei General Hospital from September 2016 to March 2019 were retrospectively analyzed and compared to those with normocomplementemia (NC). Logistic regression analysis was used to detect risk factors.

Results Of the 333 patients with pSS, 84 patients (25.23%) were presented with HC at diagnosis. The presence of hyper-IgG and anti-Ro52 antibodies was significantly more common in patients with HC. In addition to systemic involvement, pSS patients with HC had more hematological, renal, and nervous system involvement, and received more immunosuppressant treatments than NC group (p < 0.05). ESSDAI score was significantly higher in patients with HC (p < 0.05). Multivariate logistic analysis indicated that leukopenia (OR = 2.23) and hyper-IgG (OR = 2.13) were independent risk factors for pSS with HC. In addition, profound CD16/CD56+ NK-cell lymphopenia was found in pSS-HC patients. More pSS patients developed SLE in the HC group than NC group (4.76% vs. 0.80%, p = 0.04) during the follow-up.

Conclusion HC was not an uncommon manifestation of pSS and had an independent association with the main clinical and immunological features. Patients with pSS-HC had an increased possibility to develop SLE that required more positive treatment with glucocorticoids and immunosuppressants.

Key Points:
• Hypocomplementemia had an independent association with the main clinical and immunological features in primary Sjögren’s syndrome patients.
• ESSDAI score was significantly higher in patients with hypocomplementemia.
• The pSS patients with hypocomplementemia had an increased possibility to develop SLE.

Keywords Hypocomplementemia · NK cell · Primary Sjögren syndrome · Risk factor · Systemic lupus erythematosus

Lin Wei and Xin Zhifei contributed equally to this work.

Lin Wei linwei272@163.com
Fengxiao Zhang zfx9911@163.com

1 Department of Rheumatology and Immunology, Hebei General Hospital, No. 348 Heping West Road, Shijiazhuang 050051, Hebei, China
2 Department of Thoracic Surgery, Hebei General Hospital, Shijiazhuang 050051, China
3 Department of Gastroenterology and Nephrology, People’s Hospital of Huili County, Liangshan Yi Autonomous Prefecture 615100, Sichuan Province, China
4 Department of Graduate School, Hebei Medical University, Shijiazhuang 050017, China
5 Department of Stomatology, Hebei General Hospital, Shijiazhuang 050051, China
6 Department of Oncology, Hebei General Hospital, Shijiazhuang 050051, China
7 Department of Rheumatology, Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, National Clinical Research Center for Dermatologic and Immunologic Diseases, State Key Laboratory of Complex Severe and Rare Diseases, Beijing 100730, China
Introduction

Primary Sjögren’s syndrome (pSS) is a systemic autoimmune rheumatic disease characterized by lymphocytic infiltration of exocrine glands, which could lead to heterogeneous and various clinical presentations from sicca symptoms to systemic disease [1]. Approximately one-third of patients with pSS present extra-glandular manifestations, and some of these symptoms (e.g., interstitial lung disease, central nervous system [CNS] disease, and renal tubular acidosis) are associated with increased mortality. Abnormal immune response of T and B cells [2–4] recognition of self-antigens (Ro/SSA, La/SSB, and others), and subsequent activation are crucial for the cascade of events leading to the pSS pathology development [5, 6].

To date, there is increased evidence on distinct clinical phenotypes corresponding to unique autoantibodies. Various antibodies (e.g., anti-SSA, anti-SSB, anti-centromere antibodies [ACA]) have been reported to be classically correlated with parotid enlargement, Raynaud’s disease, arthritis, vasculitis, renal tubular acidosis, peripheral neuropathy, and cytopenias [7–11]. Similarly, several serologic abnormalities, such as B-cell proliferation, present special clinical features; for instance, hypergammaglobulinemia is often accompanied by extraglandular manifestations, especially with cutaneous vasculitis and pulmonary, articular, and renal involvements [12–15]. To date, few studies have addressed the clinical manifestations of hypocomplementemia (HC) or prognostic factors. This condition is not frequently observed but reported as a prognostic marker for lymphoma development in patients with pSS [16, 17].

Here, we described the clinical features and outcomes of patients with pSS with HC as the presenting feature. Our aim was to shed light on the frequency of HC in a cohort of patients with pSS and to evaluate which clinical and serological features are significantly associated with HC.

Methods

Patients

In total, the data of 333 patients with pSS who were admitted to Hebei General Hospital from September 2016 to March 2019 were retrospectively reviewed. All patients fulfilled the American-European Consensus Group 2002 revised classification criteria for pSS [18]. According to the presence of HC, our patients were divided into the study and control groups. The study was approved by the Research Ethics Committee of the Hebei General Hospital (NO. 2016070). Written informed consent was obtained from all participants.

Procedures

General data and laboratory and clinical information at onset of patients with pSS were retrospectively reviewed, including the first presentation and systemic involvements. Clinical data, such as age at diagnosis, disease duration, oral and ocular dryness, and constitutional symptoms, as well as data on joint, pulmonary, kidney, vasculitis, skin, nervous, gastrointestinal tract, and endocrine involvement were collected. The levels of complements (C3 and C4), erythrocyte sedimentation rate, CRP, immunoglobulins (IgG, IgM, and IgA), RF, anti-Ro/SSA, and anti-La/SSB were retrieved from the case records. The laboratory tests were performed at the regular hospital laboratory. The disease activity was determined according to the 2010 ESSDAI [19, 20]. Disease activity was defined as low, moderate, and high, with scores of ≤4, 5–13, and ≥14, respectively [21]. Clinical and laboratory data were collected and according to a standard protocol. The duration of follow-up was defined as the interval from diagnosis until the date of the latest data collection (May 2021) or the date of SLE diagnosed or the date of death.

Flow cytometry

Whole blood (5 ml) was collected from patients who were hospitalized before any treatment. Erythrocytes were lysed, and cells were harvested and washed twice and stained with a specific antibody at 4°C for 20 min. The following mAbs were used in this study (all from BD Pharmingen, San Diego, CA, USA): FITC-conjugated anti-CD3 mAb, phycoerythrin (PE)-conjugated anti-CD16/CD56 mAb, PE-cy7-conjugated anti-CD4 mAb, APC-conjugated anti-CD19 mAb, and APC-cy7-conjugated anti-CD8 mAb. Then, cells were subsequently washed and resuspended in phosphate-buffered saline prior to analysis. The stained cells were measured with a FACSCanto flow cytometer (Becton Dickinson, San Jose, CA, USA), and the data were analyzed using FlowJo Software (Treestar, Ashland, OR, USA).

Statistical analysis

All data were analyzed using a standard statistical package (SPSS for Windows, version 25.0; IBM Corp., Armonk, NY, USA). Data are presented as means ± standard deviations, medians and interquartile ranges, or percentage frequencies, as appropriate. Group comparisons were conducted by Student’s t-test, Mann-Whitney’s U-test, or Fisher’s exact test, as appropriate. The correlations between variables were evaluated with Spearman’s rank correlation coefficient. The potential risk factors for HC were assessed by multiple logistic regression analysis, and the results are expressed as ORs and 95% CIs. Survival was estimated using the Kaplan-Meier method. The level of significance was set at \( p < 0.05 \).
Results

Prevalence of HC in patients with pSS

The study cohort consisted of 333 patients (310 women and 23 men). The HC rate was 25.23% (84/333). Among the 84 patients with pSS with HC, 78 (92.86%) were women and 6 (7.14%) were men. Those with HC were younger than those without (49.86 ± 15.49 vs. 55.30 ± 12.38 years; \( p = 0.004 \)).

Laboratory characteristics

As shown in Table 1, the patients with pSS with HC had striking significant differences between the two groups concerning the white blood cell (WBC) count \( (p < 0.001) \), in particular the neutrophil and lymphocyte counts \( (p = 0.003 \) and \( p = 0.005 \), respectively). The C-reactive protein (CRP) level was lower in patients with pSS-HC than in those with normal complement levels \( (p < 0.001) \), although the CRP level was approximately in a normal range. Additionally, the serum rheumatoid factor (RF) level \( (21.90 [10.6–158] \text{ vs. } 16.55 [10.60–55.93]) \) was higher in the HC than in the normocomplementemia (NC) group, but the difference was not statistically significant \( (p = 0.44) \). Moreover, higher serum immunoglobulin G (IgG) levels were observed in the HC than in the NC group \( (p < 0.001) \). Further, higher presence of IgG \( (53.57\% \text{ vs. } 30.04\% , \ p < 0.001) \) and anti-Ro52 positivity \( (71.43\% \text{ vs. } 56.22\% , \ p = 0.01) \) were observed in patients with HC. Whereas, the positive rates of detecting

Table 1  Demographic and serological descriptors of patients with pSS with HC and NC

|                        | Total group \((n = 333)\) | HC group \((n = 84)\) | NC group \((n = 249)\) | \( p\)-value \(^d\) |
|------------------------|--------------------------|----------------------|------------------------|---------------------|
| Demographic features   |                          |                      |                        |                     |
| Age at onset, years    | 54 ± 13.42               | 49.86 ± 15.49        | 55.30 ± 12.38          | 0.004               |
| Disease duration, months | 48 [12–120]               | 24 [6–84]            | 60 [12–120]            | 0.004               |
| Laboratory findings    |                          |                      |                        |                     |
| White blood cell count \((\times 10^9/L)\) | 4.96 [3.95–6.27] | 4.52 [3.46–5.55] | 5.12 [4.06–6.56] | 0.001               |
| Neutrophil counts \((\times 10^9/L)\) | 2.94 [2.18–4.26] | 2.71 [2.02–3.60] | 3.11 [2.23–4.41] | 0.003               |
| Neutrophil proportion (%) | 62.33 [53.66-68.47] | 62.11 [53.62-68.00] | 62.33 [53.64-68.79] | 0.56               |
| Lymphocyte counts \((\times 10^9/L)\) | 1.51 [1.10–1.87] | 1.35 [0.98–1.72] | 1.57 [1.18–1.90] | 0.005               |
| Lymphocyte proportion (%) | 29.93 [23.34-37.93] | 29.59 [23.85-36.46] | 30.42 [23.10-38.18] | 0.90               |
| Hemoglobin (g/L)       | 122 [109.5–135]          | 118.5 [107–127]      | 122 [111–134]          | 0.007               |
| Platelet counts \((\times 10^9/L)\) | 224 [178–269] | 199 [159.25–260] | 228 [182–274]          | 0.006               |
| ESR (mm/1 h)           | 19 [9–36]                | 15.5 [7–43]          | 19 [10–35]             | 0.27                |
| CRP (mg/L)             | 3.3 [1.11–4.39]          | 1.27 [0.59–3.30]     | 3.3 [1.68–5.33]        | <0.001              |
| RF (IU/L)              | 17.10 [10.6–67.35]       | 21.90 [10.6–158]     | 16.55 [10.60–55.93]    | 0.44                |
| IgG (g/L)              | 15.24 [12.4–19.93]       | 18.13 [13.16–25.50]  | 14.90 [12.20–18.13]    | <0.001              |
| IgA (g/L)              | 2.75 [1.92–3.63]         | 2.75 [1.80–3.90]     | 2.73 [2.02–3.55]       | 0.34                |
| IgM (g/L)              | 1.17 [0.80–1.61]         | 1.12 [0.87–1.59]     | 1.18 [0.83–1.62]       | 0.48                |
| Elevated ESR (n, %)    | 151/321, 47.04           | 36/80, 45.00         | 115/241, 47.72         | 0.67                |
| Elevated CRP (n, %)    | 63/314, 20.06            | 8/76, 10.53          | 55/238, 23.11          | 0.02                |
| Hyper-IgG (n, %)       | 118/327, 36.09           | 45/84, 53.57         | 73/243, 30.04          | <0.001              |
| RF (+) (n, %)          | 150/311, 48.23           | 40/78, 51.28         | 110/233, 47.21         | 0.45                |
| ANA (+) (n, %)         | 263, 78.98               | 66, 78.57            | 197, 79.12             | 0.92                |
| Anti-RNP (+) (n, %)    | 39, 11.71               | 12, 14.29            | 27, 10.84              | 0.40                |
| Anti-Ro52 (+) (n, %)   | 200, 60.06              | 60, 71.43            | 140, 56.22             | 0.01                |
| Anti-Ro/SSA (+) (n, %) | 187, 56.16              | 54, 64.29            | 133, 53.41             | 0.08                |
| Anti-La/SSB (+) (n, %) | 79, 23.72               | 26, 30.95            | 53, 21.29              | 0.07                |
| ACA (+) (n, %)         | 45, 13.51               | 11, 13.10            | 34, 13.65              | 0.90                |
| Pathological MSG with focus score ≥1 (n, %) | 309/323, 95.67 | 78/80, 97.50 | 231/243, 95.06 | 0.53

\( pSS \), primary Sjögren’s syndrome; \( RF \), rheumatoid factor; \( ANA \), antinuclear antibodies; \( MSG \), minor salivary gland; \( ACA \), anti-centromere antibodies; \( ESR \), erythrocyte sedimentation rate; \( IgM \), immunoglobulin M; \( IgA \), immunoglobulin A; \( IgG \), immunoglobulin G; \( CRP \), C-reactive protein; \( NC \), normal complement; \( HC \), hypocomplementemia

\( ^d \) \( p \)-value: HC group vs. NC group; \*Positive RF > 20 IU/mL; **positive for ANA titers ≥ 1:320

\( p < 0.001 \) for all comparisons involving WBC, neutrophil and lymphocyte counts.

\( p < 0.001 \) for comparison involving CRP level.

\( p = 0.44 \) for comparison involving RF level.
antinuclear antibodies (ANA), ACA, anti-Ro/SSA, anti-La/SSB, and anti-RNP antibodies were not significantly different between the two groups. Besides, no significant difference in histologic evaluation of minor salivary gland, as a focus score ≥1, was observed between the two groups.

Complement and autoantibodies

In the pSS cohort, the levels of serum C3 and C4 in anti-Ro/SSA-positive were 1.02 (0.89–1.20) g/L and 0.18 (0.15–0.23) g/L, which were significantly lower than anti-Ro/SSA-negative patients (1.11 (0.96–1.22) g/L, p = 0.006; 0.20 (0.17–0.24) g/L, p = 0.004; respectively). When further stratifying for the presence or absence of anti-La/SSB antibodies, the level of serum C4 in anti-La/SSB-positive was significantly lower than anti-La/SSB-negative patients (0.16 (0.13–0.23) g/L vs. 0.20 (0.17–0.24) g/L, p = 0.001). In addition, no significant difference in complement C3 was observed between anti-La/SSB-positive and anti-La/SSB-negative patients at baseline. Whereas, at baseline, no significant differences in complement C3 and C4 were observed between RF-positive and RF-negative nor ANA-positive and ANA-negative patients (Supplementary Fig. 1).

Clinical manifestations

In our study, the patients with pSS with HC more commonly exhibited hematological involvement (67.86% vs. 51.41%; p = 0.009), thrombocytopenia (11.90% vs. 4.02%; p = 0.009), leukopenia (33.33% vs. 14.46%; p < 0.001) and lymphopenia (36.90% vs. 22.89%; p = 0.01) at pSS diagnosis (Fig. 1 and Supplementary Table 1). Compared to patients with pSS-NC, the patients in the HC group presented higher renal (11.90% vs. 4.82%, p = 0.02) and nervous system involvement (19.05% vs. 10.04%, p = 0.03). There were no significant differences in the classic symptoms of sicca syndrome, such as xerostomia, xerophthalmia, and salivary gland enlargement (p = 0.66, p = 0.99, and p = 0.58, respectively). Meanwhile, although the difference was not statistically significant, the incidence of cutaneous involvement was higher (p = 0.19), whereas the frequencies of arthritis, pulmonary involvement, and lymphatic system involvement were lower (p = 0.14, p = 0.61, and p = 0.33, respectively) in patients with pSS with HC than in those with NC.

We then evaluated associations between different immunological markers and disease phenotype. It was not the same as the system affected by other immune markers, such
as RF, anti-Ro/SSA, anti-La-SSB and ANA. Low C3 was detected in nearly a quarter of our patients, who showed a specific phenotype consisting of a high median ESSDAI score, and a high frequency of systemic activity in the renal, hematological and biological domains. C4-HC patients also showed a specific phenotype consisting of a higher frequency of abnormal diagnostic tests for xerostomia, a much higher median ESSDAI score, and a high frequency of systemic activity in the renal, nervous, and biological domains. At the baseline, all variables were statistically significant independent factors in at least two domains.

The baseline mean ESSDAI was significantly higher in the HC patients compared with the NC patients (ESSDAI 10.5 [6–16] vs. 7 [3–13]; p = 0.006). Moreover, statistically significant differences were observed in baseline complement C3 (p = 0.03) and C4 (p = 0.04) levels explored by one-way ANOVA between patients who had no/low disease activity (defined as ESSDAI score) compared with those who had moderate or high disease activity (Fig. 1).

**Lymphocyte profile in hypocomplementemia patients**

pSS patients with HC had a significantly lower number of circulating lymphocytes compared with normal complement group (1.35 [0.98–1.72] × 10^9/L vs. 1.57 [1.18–1.90] × 10^9/L, p = 0.005). Further, we assessed immunophenotyping of pSS patients with or without hypocomplementemia by flow cytometry to investigate lymphocyte profile. As shown in Supplementary Fig. 1, Supplementary Fig. 3, and Supplementary Table 2, in HC patients, a significance decrease in absolute numbers of CD3+ T cells (919.89 [669.03–1153.09]/μl vs. 1100.67 [789.87–1331.01]/ul, p = 0.02), CD3/CD4+ T cells (434.52 [308.82–632.49]/μl vs. 579.54 [399.76–779.83]/μl, p = 0.001), CD16/CD56+ NK cells (135.33 [78.99–221.78]/μl vs. 190.94 [126.82–311.10]/μl, p = 0.001) was found. Whereas the absolute numbers of CD3/CD8+ T cells and CD19+ B cells were comparable between the two groups (p = 0.55 and p = 0.54). At the meantime, CD3/CD4+ T lymphocyte percentage and CD16/CD56+ NK lymphocyte percentage were significantly reduced. Whereas, there were no significant difference in CD3+ T lymphocyte percentage, CD3/CD8+ T lymphocyte percentage, or CD19+ B lymphocyte percentage between the two groups.

**Correlations between serum complement levels and clinical characteristics, lymphocyte profile**

Spearman correlation coefficient analysis was performed to investigate the association between serum complement level and ESSDAI, laboratory parameters and lymphocyte profile in total patients at baseline. As shown in Fig. 2, serums C3 showed a significant positively correlation with C4 (r = 0.52, p < 0.001). The level of serum C3 was negatively correlated with ESSDAI (r = −0.15, p = 0.01), IgG (r = −0.18, p = 0.001), whereas positively correlated with ESR (r = 0.17, p = 0.02), CRP (r = 0.38, p < 0.001), lymphocyte (r = 0.19, p < 0.001), platelet (r = 0.29, p < 0.001), and peripheral lymphocyte subsets such as absolute numbers of CD3+ T cells (r = 0.17, p = 0.01), CD4+ T cells (r = 0.19, p = 0.002) and CD16/CD56+ N K cells (r = 0.20, p = 0.002). Similarly, serum C4 level was negatively correlated with ESSDAI (r = −0.13, p = 0.02), IgG (r = −0.31, p < 0.001), and RF (r = −0.19, p = 0.001), whereas positively correlated with CRP (r = 0.32, p < 0.001), platelet (r = 0.19, p = 0.001), and as well as absolute numbers of CD16/CD56+ NK cells (r = 0.13, p = 0.048).

**Risk factors for HC in patients with pSS**

Multivariate analysis confirmed that leukopenia (odds ratio [OR] = 2.23, 95% confidence interval [CI] 1.18–4.23, p = 0.01) and hyper-IgG (OR = 2.13, 95% CI 1.22–3.72, p = 0.01) were independent predictors of HC in patients with pSS (Table 2).

**Therapeutic regimens and follow-up examinations**

All pSS patients were treated, including glucocorticoids (GCs) alone, GCs combined with immunosuppressant agents (GCs plus IM), GCs combined with rituximab (RTX) or hydroxychloroquine alone. In the pSS-HC group, 11 (13.10%) patients received GC monotherapy. Thirty-five (41.67%) patients received hydroxychloroquine alone. One (1.19%) patient received GCs plus RTX. Others were treated with GCs plus IM or IM monotherapy, including leflunomide (n = 15, 17.86%), mycophenolate mofetil (MMF) (n = 4, 4.76%), cyclosporin A (n = 5, 5.95%), iguratimod (n = 3, 3.57%), and cyclophosphamide (n = 1, 1.19%). While GCs-based therapies (GCs alone or in combination with IM/RTX) were used more common in HC group (29.76% vs 21.29%), the difference was not statistically significant (p = 0.11). When compared with NC group, more HC patients received MMF (4.76% vs. 0.80%, p = 0.04) and cyclosporin A (5.95% vs. 1.20%, p = 0.03).

The level of serum C3 and C4 significantly increased after treatment (p < 0.05), but still not to the normal range at the third month. During a similar follow-up time (34.03 ± 10.47 months vs. 32.78 ± 12.02 months, p = 0.28), more pSS patients developed SLE in the HC group (n = 4, 4.76%) than NC group (n = 2, 0.80%, p = 0.04). With a mean follow-up of 34.50 ± 10.19 months (range 24–50 months) after diagnosis of pSS, these patients developed SLE. Further, one patient (1.19%) in HC group died, which was comparable to NC group (n = 3, 1.20%, p = 0.99). The ESSDAI in HC
patients was still higher than that in NC patients (6 (1.5–10) vs 4 (0–7); p = 0.001) at the last follow-up visit, which was significantly lower compared to baseline at diagnosis (10.5 (6–16), p < 0.001). In addition, disease activity was low in 14 (16.67%) patients, moderate in 46 (54.76%), and high in 24 (28.57%) at baseline in HC patients. After therapy, disease activity was no activity in 18 (23.38%) patients, low in 32 (13.56%), moderate in 96 (40.68%), and high in 20 (8.47%) (Fig. 3).

**Discussion**

In this study, for the first time, we confirmed the association of HC with the phenotype of the disease not only at diagnosis but also at the end of follow-up in the large cohort of Chinese pSS patients. Complement values were measured in 333 pSS patients and were low in 84 (25.23%). HC had an independent association with the main clinical and immunological features, including a lower mean age at diagnosis, a higher serum IgG level, a higher ESSDAI score both at diagnosis and at the end of follow-up, and a higher frequency of activity in hematological, renal, and nervous system. To the best of our knowledge, this study evaluated the lymphocyte profile in pSS-HC patients for the first time, and profound CD16/CD56+ NK lymphopenia and decreased numbers of CD4+ T-cell cells were the most distinguishing features of the HC group. As a marker of pSS activity, the measurement of C3 and C4 levels was
recommended to evaluate and monitor the condition of patients with pSS. In addition, multivariate analysis identified leukopenia and elevated IgG as risk factors for HC in patients with pSS.

The prevalence of low C3 and C4 levels was found to be 22.82% and 8.71% in this study, which was similar to previous studies. Especially, Baldini et al. [22] detected low C3 and C4 levels in 15.3% and 11.1% of 1115 patients, respectively. Jordán-González et al. [23] found low C3 and C4 levels in 9.57% and 13.83% of 94 patients, respectively, while Lin et al. [24] reported low C3 and C4 levels in 14.4% and 16.5% of their participants, respectively. The different ethnicity, cohort size, disease severity degrees, and cut-off levels of the complement assays used may be attributed to the different prevalence of HC observed in these studies.

In a large international multicenter study and another study including 921 Spanish pSS patients, reduced C3 and C4 complement fractions at the pSS diagnosis were observed and these findings were associated with disease activity [25, 26]. Besides, a systematic review and meta-analysis were performed and found that low C3 [RR 2.14 (95% CI 1.38, 3.32)] and C4 levels [RR 3.08 (95% CI 2.14, 4.42)] were consistently associated with higher mortality risk [27]. These results suggested that complement consumption may contribute to the pSS etiopathogenesis. We assessed for the first time that HC not only correlates with disease activity at diagnosis, but also plays a central role in predicting outcome as prognostic marker. The current study is, to the best of our knowledge, the first to describe the detailed characteristics of HC in pSS patients not only.
Several previous studies have explored the potential role for abnormal complement activation in pSS. Especially, Zadura et al. found that with the widespread autoantibody production, the C4BP levels decreased in parallel with the C3 and C4 levels in active patients with pSS, which suggested that disturbed complement regulation may contribute to pSS pathogenicity [28]. Interestingly, Sudzius et al. reported that the serum C4d level was significantly lower in anti-SSA/SSB Ab seropositive than in seronegative patients with pSS and was also correlated with the C4 and anti-SSB Ab levels and the κ/λ ratio. They proposed that the C4d level can be an appropriate marker of complement activation in patients with pSS with Abs [29]. Evans et al. reported the presence of positive staining for C9 around the tubular basement membranes in patients with pSS-TIN [30]. Moreover, Xia et al. performed a retrospective study and investigated the prevalence and localization of C4d deposits in renal biopsy tissues of patients with pSS. They found that glomerular C4d deposition was observed in all patients with pSS-related membranous nephropathy (MN) and suggested a role for the mannan-binding lectin pathway of complement activation in patients with pSS-related MN [31]. Furthermore, our lymphocyte profile studies revealed that, for the first time, significant decreases in absolute numbers of CD16/CD56+ NK cells were found in HC patients, and had a positive correlation with both C3 and C4, which might enforce the concept that complement activation affects the function of NK cells [32]. With the evidence of the complement system in vivo activation, these results suggested that complement consumption affects pSS pathophysiology. Therefore, the presence of HC in patients with pSS may signify the presence of disease activity. This is consistent with our findings, which demonstrated a significant higher ESSDAI in patients with pSS-HC.

HC had no influence on the glandular disease expression, but played an important role in driving a multisystemic phenotype with statistically significant higher frequencies, including renal, nervous, and hematological involvement in our study. In recent years, there has been an increasing interest in renal diseases associated with pSS. Specifically, scientists are interested in whether the reduction of complement in pSS patients is related to kidney involvement. In our study, HC was more commonly found in patients with renal disease than in those in other groups, which was in line with previous findings [33, 34]. However, this finding was contradicted by other studies. Especially, Zhao et al. found that hypokalemic paralysis, assumed to be a surrogate of renal damage, did not show any association with low complement [35]. Moreover, Yang et al. published a retrospective study, which included 103 patients with pSS who had undergone kidney biopsy. Interestingly, no significant differences were observed between patients with and without renal disease [36]. Combined with the pathological findings, it was suggested that complement activation may have contributed to Sjogren's nephritis development.

Nervous system involvement, ranging from the peripheral nervous system to the CNS, is known to be multifaceted and possibly underestimated in pSS. Neurological disease might have arose many years before pSS diagnosis and was found to contribute to damage in patients with pSS. Our study is one of the first to report that nervous system involvement correlates with HC in patients with pSS. Besides, we found that there was a relationship between the incidences of nervous system involvement and HC, which is consistent with the findings by Ye et al., who found that patients with pSS with neurological involvement showed reduced C3 levels (p < 0.05). Additionally, low C3 level was found to be a potential risk factor for neurological involvement in younger patients with pSS [37]. Moreover, arising data supported that the complement system may facilitate various neuroinflammation activities [38, 39]. Because of the evidence indicating that the complement levels play key roles in driving multiple nervous pathologies, the complement system may be a potential therapeutic target for treating brain injury in patients with pSS [40].

What’s more, HC was strongly associated with disease prognosis and outcomes. It is well known that the complement system plays a pivotal role in SLE development, and previous data reported that patients with pSS with low complement levels are more likely to develop SLE. In a retrospective study including 55 patients with Sjogren’s syndrome-onset SLE (SS/SLE), Yunjiao et al. revealed that these patients showed a significantly higher frequency of low complement levels (C3, 54.5% vs. 12.7%; C4, 41.8% vs. 7.3%, p = 0.000). Additionally, low C3 and C4 levels were independent risk factors of SS/SLE development (low C3 levels, RR = 9.659, p = 0.000; low C4 levels, RR = 6.035, p = 0.007) [41]. Our study showed that pSS with HC can precede SLE by several years, confirming previously published reports of patients with long-standing pSS who eventually developed a systemic disorder that fulfilled the criteria for SLE [42]. The coexistence of SS and SLE was first demonstrated in 1959 [43] and has since been demonstrated by multiple studies. Some studies have shown that pSS with extraglomerular manifestations can precede SLE by several years and reports suggest that 3.7–19.6% of SLE patients are accompanied by SS. Zufferey et al. found that 4 (7.5%) SS patients developed SLE after a long-term follow-up (range 8–18 years) of 55 SS patients [44]. Manoussakis et al. evaluated 283 SLE patients and found that SS was identified in 26 SLE patients (9.2%), of which the SS preceded the development of lupus in 18 of them (69.2%)
Clinical Rheumatology (2022) 41:2091–2102

might be related to cryoglobulinemia, such as the kidney, the enrolled patients, especially the ESSDAI domains that
occurrence [50, 51]. HC was thought to be associated with
mutations, increase the risk of lymphoid malignancy
autoreactive B-cells in such patients and further, through
fied, low C3/C4 levels may help improve the survival of
generation in patients with pSS have not been well identi-
fication is needed to establish definitive diagnosis
specific for SLE and very rare in pSS, are negative. More
antibodies against double-stranded DNA or Sm, which are
occur in SLE patients. In addition, these two entities share
features [45]. The exact cause of emerging SLE in patients
with pSS has not been well known yet. They share sev-
ral possible underlying etiopathogenic aspects, including
numerous genetic factors, epigenetic, environmental, and
hormonal factors [47–49]. Thus, careful investigation
of SLE in patients with pSS diagnosis is recommended.
However, pSS and SLE cannot be differentiated definitely.
One of the main challenges faced by studies of pSS is that
several of the systemic features, including lymphopenia,
central and peripheral nervous system manifestations, also
occur in SLE patients. In addition, these two entities share
several immunological features, including the presence of
anti-SSA and/or SSB antibodies. Therefore, it is difficult
to distinguish systemic pSS from SLE, especially when
antibodies against double-stranded DNA or Sm, which are
specific for SLE and very rare in pSS, are negative. More
clinical research is needed to establish definitive diagnosis
criterion to distinguish these two important conditions.

Although the mechanisms underlying lymphoma patho-
genesis in patients with pSS have not been well identi-
fied, low C3/C4 levels may help improve the survival of
autoreactive B-cells in such patients and further, through
mutations, increase the risk of lymphoid malignancy
occurrence [50, 51]. HC was thought to be associated with
lymphoma development and worse prognosis in patients
with pSS [17, 22, 52]. In our study, it is noteworthy that
such patients with HC usually presented hypergammaglob-
ulinemia, anemia, leukopenia, and, especially, lymphocy-
topenia at the time of pSS diagnosis, indicating that these
conditions are strong predictors of lymphoma develop-
ment. In accordance with previous reports, we confirmed
the preponderance of high risk of lymphoma development
in the HC group.

The limitations of this study include several aspects. First,
the study has a retrospective design. Second, we only tested
some patients with suspected cryoglobulinemia, and the
results were all negative, so cryoglobulin was not routinely
checked in all our patients. This might be partly because
cryoglobulinemia was relatively rare in Chinese pSS patients
[53], when compared with European studies [22, 54, 55].
However, we conducted a detailed systematic evaluation of
the enrolled patients, especially the ESSDAI domains that
might be related to cryoglobulinemia, such as the kidney,
mucous membrane, and nervous system. What’s more, there
were no hepatitis C and lymphoma patients in our group. To
address this issue, a future study analyzing the predictive
value of cryoglobulinemia in Chinese patients with pSS is
required. Third, in this study, potential clinical factors in
estimating the prognosis, such as longer follow-up changes
in C3/C4 levels, were not well evaluated. Further prospective
studies with a larger number of long-term follow-up patients
with pSS are needed.

In conclusion, we confirmed that HC was associated with
specific clinical and immunological features in patients with
pSS. It is noteworthy that such patients with HC usually
presented hypergammaglobulinemia, anemia, leukopenia,
and, especially, CD16/CD56 (+) NK lymphocytopenia at
the time of pSS diagnosis, thus highlighting the increased
risk of lymphoproliferative disease development. In addi-
tion, complement level was a potential marker of disease
activity in pSS. Furthermore, this study revealed that HC
might help in the early identification of patients with pSS
who need to receive more aggressive treatments. Thus, com-
plement detection in pSS is clinically useful, especially for
the diagnosis and prognosis. However, further large-scale
prospective studies are needed to confirm these findings.

Supplementary Information The online version contains supplemen-
tary material available at https://doi.org/10.1007/s10067-022-06135-w.

Author contribution Conception and design: W.L., ZF. X., W. Z.;
acquisition of data: ZF. X., XR. N., L.Y., SY. G.; analysis and inter-
pretation of data: YX. L., XR. N., ML. L., YS. S.; statistical analysis:
Y.L., W.L.; drafting the article or revising it critically for important
intellectual content: all authors; final approval of the version published:
all authors.

Funding This work was funded by the grant from the National Nature
Science Foundation of China (No. 81801630) and the National Nature
Science Foundation of Hebei Province (No. H2018307047).

Data availability The datasets used or analyzed during the current
study are available from the corresponding author on reasonable
request.

Declarations

Disclosures None.

Open Access This article is licensed under a Creative Commons Attri-
tution 4.0 International License, which permits use, sharing, adapta-
tion, distribution and reproduction in any medium or format, as long
as you give appropriate credit to the original author(s) and the source,
provide a link to the Creative Commons licence, and indicate if changes
were made. The images or other third party material in this article are
included in the article’s Creative Commons licence, unless indicated
otherwise in a credit line to the material. If material is not included in
the article’s Creative Commons licence and your intended use is not
permitted by statutory regulation or exceeds the permitted use, you will
need to obtain permission directly from the copyright holder. To view a
copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
References

1. Goules AV, Tzioufas AG (2016) Primary Sjögren's syndrome: clinical phenotypes, outcome and the development of biomarkers. Autoimmun Rev 15:695–703. https://doi.org/10.1016/j.autrev.2016.03.004

2. Ibrahim HM (2019) B cell dysregulation in primary Sjögren's syndrome: a review. Jpn Dental Sci Rev 55:139–144. https://doi.org/10.1016/j.jdrsr.2019.09.006

3. Lin W, Jin L, Chen H, Wu Q, Fei Y, Zheng W, Wang Q, Li P, Li Y, Zhang W, Zhao Y, Zeng X, Zhang F (2014) B cell subsets and dysfunction of regulatory B cells in IgG4-related diseases and primary Sjögren's syndrome: the similarities and differences. Arthritis Res Ther 16:R118. https://doi.org/10.1186/ar4571

4. Hamza N, Bos NA, Kallenberg CG (2012) B-cell populations and sub-populations in Sjögren's syndrome. Presse Med Paris (France) 41:e475–e483. https://doi.org/10.1016/j.jpm.2012.05.021

5. Parisi D, Chiavasso C, Perret J, Soyfoo MS, Delporte C (2020) Current state of knowledge on Primary Sjögren's Syndrome, an autoimmune exocrinopathy. J Clin Med 9:2299. https://doi.org/10.3390/jcm9072299

6. Nocturne G, Mariette X (2018) B cells in the pathogenesis of primary Sjögren syndrome. Nat Rev Rheumatol 14:133–145. https://doi.org/10.1038/rheum.2018.1

7. Wei L, Zhifei X, Xiaoran N, Meilu L, Yang L, Xiyuan L, Xiuying R, Yashuang S, Jingjing C, Shaoying G, Liu Y, Lijun S, Fengxiai ZWen Z (2021) Patients with early-onset primary Sjögren’s syndrome have distinctive clinical manifestations and circulating lymphocyte profiles. Rheumatology (Oxford, England). https://doi.org/10.1093/rheumatology/keab367

8. Lin W, Xin Z, Ning X, Li Y, Ren X, Su Y, Liu M, Guo S, Yang L, Liu Y, Zhan F, Zhang W (2021) Clinical features and risk factors of Raynaud's phenomenon in primary Sjögren's syndrome. Clin Rheumatol. https://doi.org/10.1007/s10067-021-05749-w

9. Baer AN, Medrano L, McAdams De Marco MG, Niadek TJ (2016) Association of anticitrulline antibodies with more severe exocrine glandular dysfunction in Sjögren's syndrome: analysis of the Sjögren's International Collaborative Clinical Alliance Cohort. Arthritis Care Res 68:1554–1559. https://doi.org/10.1002acr.22859

10. Ramos-Casals M, Solans R, Rosas J, Camps MT, Gil A, Del Pino-Montes J, Calvo-Alen J, Jiménez-Alonso J, Micó ML, Beltrán J, Belenguer R, Pallarés L (2008) Primary Sjögren syndrome in Spain: clinical and immunologic expression in 1010 patients. Medicine 87:210–219. https://doi.org/10.1097/MED.0b013e318181e6af

11. Mavragani CP, Tzioufas AG, Moutsopoulos HM (2000) Sjögren's syndrome: autoantibodies to cellular antigens. Clinical and molecular aspects. Int Arch Allergy Immunol 123:46–57. https://doi.org/10.1159/000024423

12. Fauchais AL, Ouattara B, Gondran G, Lalloué F, Petit D, Ly K, Lambert M, Launay D, Loustad-Ratti V, Bezanahari H, Liozon E, Hachulla E, Jaubert MO, Vidal EH. E. H. E. N. PY (2010) Articular manifestations in primary Sjögren's syndrome: clinical significance and prognosis of 188 patients. Rheumatology (Oxford, England) 49:1164–1172. https://doi.org/10.1093/rheumatology/keq047

13. Tsukamoto M, Suzuki K, Takeuchi T (2019) Ten-year observation of patients with primary Sjögren’s syndrome: initial presenting characteristics and the associated outcomes. Int J Rheum Dis 22:929–933. https://doi.org/10.1111/1756-185x.13464

14. Ter Borg EJ, Kelder JC (2017) Is extra-glandular organ damage in primary Sjögren’s syndrome related to the presence of systemic auto-antibodies and/or hypergammaglobulinemia? A long-term cohort study with 110 patients from the Netherlands. Int J Rheum Dis 20:875–881. https://doi.org/10.1111/1756-185x.13070

15. Baimpa E, Dahabreh IJ, Voulgareli M, Moutsopoulos HM (2009) Hematologic manifestations and predictors of lymphoma development in primary Sjögren syndrome: clinical and pathophysiologic aspects. Medicine 88:284–293. https://doi.org/10.1097/MD.0b013e3181b76ab5

16. Papageorgiou A, Voulgareli M, Tzioufas AG (2015) Clinical picture, outcome and predictive factors of lymphoma in Sjögren syndrome. Autoimmun Rev 14:641–649. https://doi.org/10.1016/j.autrev.2015.03.004

17. Solanas-Laqué R, López-Hernández A, Bosch-Gil JA, Palacios A, Campillo M, Vilardell-Tarrés M (2011) Risk, predictors, and clinical characteristics of lymphoma development in primary Sjögren’s syndrome. Semin Arthritis Rheum 41:415–423. https://doi.org/10.1016/j.semarthrit.2011.04.006

18. Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, Daniels TE, Fox PC, Fox RJ, Kassan SS, Pillemer SR, Talal N, Weisman MH (2002) Classification criteria for Sjögren’s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 61:554–558. https://doi.org/10.1136/ard.61.6.554

19. Seror R, Theander E, Brun JG, Ramos-Casals M, Valim V, Dorner T, Bootsmah A, Tzioufas A, Solans-Laqué R, Mandl T, Gottenberg JE, Hachulla E, Sivils KL, Ng WF, Fauchais AL, Bombardieri S, Valesini G, Bartoloni E, Saura A et al (2015) Validation of EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient indexes (ESSPRI). Ann Rheum Dis 74:859–866. https://doi.org/10.1136/annrheumdis-2014-204615

20. Seror R, Ravaud P, Bowman SJ, Baron G, Tzioufas A, Theander E, Gottenberg JE, Bootsmah H, Mariette X, Vitali C (2010) EULAR Sjogren’s syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjögren’s syndrome. Ann Rheum Dis 69:1103–1109. https://doi.org/10.1136/ard.2009.110619

21. Seror R, Bootsmah H, Saura A, Bowman SJ, Theander E, Brun JG, Baron G, Le Guern V, Devauchelle-Pensec V, Ramos-Casals M, Valim V, Dorner T, Tzioufas A, Gottenberg JE, Solans Laque R, Mandl T, Hachulla E, Sivils KL, Ng WF et al (2016) Defining disease activity states and clinically meaningful improvement in primary Sjögren’s syndrome with EULAR primary Sjögren’s syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI). Ann Rheum Dis 75:382–389. https://doi.org/10.1136/annrheumdis-2014-206008

22. Baldini C, Cepe P, Quaruccio L, Priori R, Bartoloni E, Alunno A, Gattamelata A, Maset M, Modesi M, Tavoni A, De Vita S, Gerli R, Valesini G, Bombardieri S (2014) Primary Sjögren’s syndrome as a multi-organ disease: impact of the serological profile on the clinical presentation of the disease in a large cohort of Italian patients. Rheumatology (Oxford, England) 53:839–844. https://doi.org/10.1093/rheumatology/ket427

23. Jordán-González P, Gago-Piñero R, Varela-Rosario N, Pérez-Ríos N, Vilà LM (2020) Characterization of a subset of patients with primary Sjögren’s syndrome initially presenting with C3 or C4 hypocomplementemia. Eur J Rheumatol 7:112–117. https://doi.org/10.5152/eurheuma.2020.19132

24. Lin DF, Yan SM, Zhao Y, Zhang W, Li MT, Zeng XF, Zhang FC, Dong Y (2010) Clinical and prognostic characteristics of 573 cases of primary Sjögren’s syndrome. Chin Med J 123:3252–3257
25. Brito-Zerón P, Acar-Denizli N, Ng WF, Zeher M, Rasmussen A, Mandl T, Seror R, Li X, Baldini C, Gottenberg JE, Danda D, Quattrocchio L, Priori R, Hernandez-Molina G, Armagan B, Kruize AA, Kwok SK, Kvarnström M, Prapratnik S et al (2018) How immunological profile drives clinical phenotype of primary Sjögren's syndrome at diagnosis: analysis of 10,500 patients (Sjögren Big Data Project). Clin Exp Rheumatol 36:102–112

26. Ramos-Casals M, Brito-Zerón P, Solans R, Camps MT, Casanova A, Sopena B, Diaz-Lopez B, Rascon FJ, Qanneta R, Fraile G, Perez-Alvarez R, Callejas JL, Ripolli M, Pinilla B, Akasi M, Fonseca E, Canora J, Nadal ME, de la Red G et al (2014) Systemic involvement in primary Sjögren's syndrome evaluated by the EULAR-SS disease activity index: analysis of 921 Spanish patients (GEAS-SS Registry). Rheumatology (Oxford) 53:321–331. https://doi.org/10.1093/rheumatology/ket349

27. Singh AG, Singh S, Matteson EL (2016) Rate, risk factors and causes of mortality in patients with Sjögren's syndrome: a systematic review and meta-analysis of cohort studies. Rheumatology (Oxford) 55:450–460. https://doi.org/10.1093/rheumatology/kev354

28. Zadura AF, Theander E, Blom AM, Trouw LA (2009) Complement inhibitor C4b-binding protein in primary Sjögren's syndrome and its association with other disease markers. Scand J Immunol 69:374–380. https://doi.org/10.1111/j.1365-3083.2009.02229.x

29. Sudzis G, Meliauskaitė D, Siarys A, Viliene R, Butrimiene I, Characiejus D, Dumalakienė I (2014) Could the complement component C4 or its fragment C4d be a marker of the more severe conditions in patients with primary Sjögren’s syndrome? Rheumatol Int 34:235–241. https://doi.org/10.1007/s00296-013-2885-y

30. Evans RD, Laing CM, Curtin C, Walsh SB (2016) Tubulointerstitial nephritis in primary Sjögren syndrome: clinical manifestations and response to treatment. BMC Nephrology 17:2. https://doi.org/10.1186/s12891-015-0858-x

31. Xia W, Gao B, Duan L, Li Y, Wen Y, Chen L, Li X, Zheng F, Li M (2019) Clinical significance of C4d deposition in renal tissues from patients with primary Sjögren's syndrome-a preliminary study. BMC Nephrol 20:189. https://doi.org/10.1186/s12882-019-1341-y

32. Min X, Liu C, Wei Y, Wang N, Yuan G, Liu D, Li Z, Zhou W, Li K (2014) Expression and regulation of complement receptors by human natural killer cells. Immunobiology 219:671–679. https://doi.org/10.1016/j.imbio.2014.03.018

33. Luo J, Hua YY, Wang JW, Guo H (2019) High-risk indicators of renal involvement in Primary Sjögren's Syndrome: a clinical study of 1002 cases. J Immunol Res 2019:3952392. https://doi.org/10.1155/2019/3952392

34. Luo J, Xu S, Lv Y, Huang X, Zhang H, Zhu X, Wang X (2019) Clinical features and potential relevant factors of renal involvement in primary Sjögren's syndrome. Int J Rheum Dis 22:182–190. https://doi.org/10.1111/1756-185x.13429

35. Zhao L, Li Y, Wang L, Li XF, Huang CB, Wang GC, Zhang XW, Zhang ZL, Zhang X, Xiao WG, Dai L, Wang YF, Hu SX, Li HB, Gong L, Liu B, Sun LY, Zhang MJ, Zhang X et al (2015) Primary Sjögren syndrome in Han Chinese: clinical and immunological characteristics of 483 patients. Medicine 94:e667. https://doi.org/10.1097/md.0000000000000667

36. Yang HD, Wang J, Wen YB, Fei YY, Jiang MD, Zhou MY, Zhang W, Li H, Li XM, Zhang FC, Li XW, Zhang X, Chen LM (2018) Renal involvement in primary Sjögren’s syndrome: a retrospective study of 103 biopsy-proven cases from a single center in China. Int J Rheum Dis 21:223–229. https://doi.org/10.1111/1756-185x.13182

37. Ye W, Chen S, Huang X, Qin W, Zhang T, Zhu X, Zhu X, Lin C, Wang X (2018) Clinical features and risk factors of neurological involvement in Sjögren’s syndrome. BMC Neurosci 19:26. https://doi.org/10.1186/s12868-018-0427-y

38. Brennan FH, Anderson AJ, Taylor SM, Woodruff TM, Ruitenbergen MJ (2012) Complement activation in the injured central nervous system: another dual-edged sword? J Neuroinflammation 9:137. https://doi.org/10.1186/1742-2094-9-137

39. Carpanini SM, Torvell M, Morgan BP (2019) Therapeutic inhibition of the complement system in diseases of the central nervous system. Front Immunol 10:362. https://doi.org/10.3389/fimmu.2019.00362

40. Mallah K, Couch C, Borucki DM, Toutouji A, Alshareef M, Tomlinson S (2020) Anti-inflammatory and neuroprotective agents in clinical trials for CNS disease and injury: where do we go from here? Front Immunol 11:2021. https://doi.org/10.3389/fimmu.2020.02021

41. Yang Y, Li Z, Wang L, Zhang F (2013) The clinical and laboratory characteristics of Sjögren’s syndrome that progresses to systemic lupus erythematosus: a retrospective case-control study. Int J Rheum Dis 16:173–177. https://doi.org/10.1111/1756-185x.12088

42. Yang Y, Li Z, Wang L, Zhang F (2013) The clinical and laboratory characteristics of Sjögren’s syndrome that progresses to systemic lupus erythematosus: a retrospective case-control study. Int J Rheum Dis 16:173–177

43. Moutsopoulos HMT, Mann DL, Klippel JH, Fauci AS, Frank MM, Lawley TJ, Hamburger MI (1980) Sjögren’s syndrome (Sicca syndrome): current issues. Ann Intern Med 92:212–226

44. Zufferey P, Meyer OC, Bourgeois P, Vassyairat M, Kahn MF (1995) Primary systemic Sjögren’s syndrome (SS) preceding systemic lupus erythematosus: a retrospective study of 4 cases in a cohort of 55 SS patients. Lupus 4:23–27

45. Manoussakis MN, Georgopoulos C, Zintzaras E, Spyropoulou M, Stavropoulou A, Skopoulis FN, Moutsopoulos HM (2004) Sjögren’s syndrome associated with systemic lupus erythematosus: a retrospective and laboratory profiles and comparison with primary Sjögren’s syndrome. Arthritis Rheum 50:882–891. https://doi.org/10.1002/art.20093

46. Yao Q, Altman RD, Wang X (2012) Systemic lupus erythematosus with Sjogren syndrome compared to systemic lupus erythematosus alone: a meta-analysis. J Clin Rheumatol 18:28–32. https://doi.org/10.1097/RHU.0b013e31823ebd7f

47. Psinou K, Papagoulias I, Papanastassio AD, de Lastic AL, Rodi M, Spanidea P, Degen SE, Georgiou P, Mouzaki A (2018) Clinical and immunological parameters of Sjögren’s syndrome. Autoimm Rev 17:1053–1064. https://doi.org/10.1016/j.autrev.2018.05.005

48. Aggarwal R, Anaya JM, Koelsch KA, Kurien BT, Scofield RH (2015) Association between secondary and primary Sjogren’s syndrome in a large collection of lupus families. Autoimmune Dis 2015:298506. https://doi.org/10.1155/2015/298506

49. Pasoto SG, Adriano de Oliveira Martins V, Bonfá E (2019) Sjogren’s syndrome and systemic lupus erythematosus: links and risks. Open Access Rheumatol 11:33–45. https://doi.org/10.2147/OARRR.S167783

50. Carroll MC (2004) The complement system in B cell regulation. Mol Immunol 41:141–146. https://doi.org/10.1016/j.molimm.2004.03.017

51. Rozendaal R, Carroll MC (2007) Complement receptors CD21 and CD35 in humoral immunity. Immunol Rev 219:157–166. https://doi.org/10.1111/j.1600-065X.2007.00556.x
52. Theander E, Manthorpe R, Jacobsson LT (2004) Mortality and causes of death in primary Sjögren’s syndrome: a prospective cohort study. Arthritis Rheum 50:1262–1269. https://doi.org/10.1002/art.20176

53. Shi XH, Ma J, Li C, Wen YB, Li H, Li MX, Li XW, Li XM (2014) Clinical features of 30 patients with cryoglobulinemia. Zhongguo yi xue ke xue yuan xue bao. Acta Acad Med Sin 36:639–644. https://doi.org/10.3881/j.issn.1000-503X.2014.06.015

54. Pertovaara M, Pukkala E, Laippala P, Miettinen A, Pasternack A (2001) A longitudinal cohort study of Finnish patients with primary Sjögren’s syndrome: clinical, immunological, and epidemiological aspects. Ann Rheum Dis 60:467–472. https://doi.org/10.1136/ard.60.5.467

55. Alamanos Y, Tsifetaki N, Voulgari PV, Venetsanopoulou AI, Sioszos C, Drosos AA (2006) Epidemiology of primary Sjögren’s syndrome in north-west Greece, 1982-2003. Rheumatology (Oxford, England) 45:187–191. https://doi.org/10.1093/rheumatology/kei107

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.